Third, we found LBH was significantly overexpressed in prostate cancer (PRAD) in both the TCGA and Oncomine patient cohorts (>1.6-fold; p < 0.003) that together encompass more than 500 primary prostate cancers, and in prostate cancer tissues by IHC. This evidence concerns the gene LBH and prostate carcinoma.